HAIXI PHARMA
02637Listed醫療健康 · 海西制药是一家商业化阶段的制药公司，专注于仿制药和四款创新药研发。
High attention
80.9
/100
- Offer price
- HK$86.40
- Final offer price
- HK$86.40
- Lot / entry fee
- 50 shares · HK$4K
- Proceeds
- HK$993.6M
- Sponsor
- Huatai Financial / CMB International
- Est. margin oversub.
- 2469.0x
- Public oversub.
- 3165.1x
- One-lot win rate
- 1.0%
- First-day return
- +20.6%
Offer starts
Oct 9
Offer closes
Oct 14
Grey market
Oct 16
Listing
Oct 20
AI reference scoring and scenarios
After grey market
After grey market L1 heat score
80.9/ 100
Data coverage High
Target
Historical calibration
Listing-day trend
Strong positivePartial basis
Up probability
92.1%
First-day reference range
+12.8% – +58.6%
Published outcome check
First-day resultUp+20.6%
Our call: Trend call valid
Covered 19/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Good qualityCornerstone lockup
Weak supportPost-lockup offer value
Medium scarcityRecent same-rule trend
Strong trendRecent same-type trend
Strong trendRecent sector trend
Strong trendValuation
Average appealFundamental quality
High qualityGrowth quality
High qualityProfitability
Good qualityCash runway
—Customer concentration
High riskCornerstone quality
Weak supportSponsor record
Strong recordGreenshoe arrangementNo greenshoe
Stabilizer track record
—A-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
High heatInternational placing
High heatFinal pricing position
—Actual greenshoe use
—Grey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
After grey marketThe analysis report for this IPO is being generated.